Schmeiser T, Kurrle E, Arnold R, Wiesneth M, Bunjes D, Hertenstein B, Kern W, Heit W, Heimpel H
Department of Internal Medicine, University of Ulm, FRG.
Scand J Infect Dis. 1988;20(6):625-31. doi: 10.3109/00365548809035663.
48 patients treated with bone marrow transplantation (BMT) received the quinolone norfloxacin (NOR) in a total decontamination (TD-NOR, n = 36) or selective decontamination (SD-NOR, n = 12) regimen and were compared with a historical control group of 48 BMT patients receiving oral non-absorbable antibiotics (TD-NAA, n = 31 and SD-NAA, n = 17). 17/36 patients (47%) of group TD-NOR and 16/31 patients (52%) of group TD-NAA remained free of febrile episodes and infections. 4/12 patients (33%) of group SD-NOR and only 1/17 patients (6%) of group SD-NAA remained free of fever and infections. The use of norfloxacin in selective decontamination resulted in a statistically significant lower incidence of fever days than in patients receiving SD-NAA (p less than 0.001). These data suggest that norfloxacin may replace non-absorbable antibiotics in total and in selective decontamination regimens used for infection prophylaxis in BMT recipients.
48例接受骨髓移植（BMT）的患者在全肠道去污（TD-NOR，n = 36）或选择性去污（SD-NOR，n = 12）方案中接受喹诺酮类药物诺氟沙星（NOR）治疗，并与48例接受口服非吸收性抗生素的BMT患者历史对照组（TD-NAA，n = 31和SD-NAA，n = 17）进行比较。TD-NOR组17/36例患者（47%）和TD-NAA组16/31例患者（52%）未出现发热发作和感染。SD-NOR组4/12例患者（33%）和SD-NAA组仅1/17例患者（6%）未出现发热和感染。在选择性去污中使用诺氟沙星导致发热天数的发生率在统计学上显著低于接受SD-NAA的患者（p < 0.001）。这些数据表明，在用于BMT受者感染预防的全肠道去污和选择性去污方案中，诺氟沙星可能替代非吸收性抗生素。
